The Latest Regenerative Medicine Articles from Streetwise Reports


Proteostasis Therapeutics Reports Positive Results from European Cystic Fibrosis Research

  ()
Proteostasis Therapeutics' shares traded higher after the company reported positive results in its European Cystic Fibrosis study of organoids grown from human stem cells. The firm believes the ongoing ex-vivo study supports initiation of a human clinical trial in mid-2020, and potential for a Marketing Authorization Application in 2021. read more >
News Update

Regenerative Medicine Firm Advances Multifaceted Pipeline

News Update
  ()
The company continues advancing its cell therapies and medical device. read more >

IVERIC bio Shares Double After Announcing Phase 2b AMD Topline Data

  ()
Shares of IVERIC bio traded 100% higher after reporting that it successfully met its primary endpoint in its Phase 2b age-related macular degeneration study for Zimura. read more >

Fiscal Year 'Reads Well' for Regenerative Medicine Company

Research Report
  ()
The firm's final quarter and full-year results are reviewed in a Ladenburg Thalmann report. read more >
Showing Results: 1 to 4 of 4

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"From a stock perspective, 2019 was a clear breakout year for DRRX." ❭
– Ed Arce, H.C. Wainwright & Co.